EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer
Clinical trial NCT05715216 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05715216
- Sponsor
- M.D. Anderson Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-01
- Primary completion
- 2025-04-30
- Enrollment
- 23
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.